Medline Inc. announces pricing of secondary offering of class A common stock
Rhea-AI Summary
Medline (Nasdaq: MDLN) priced a secondary offering of 75,000,000 Class A shares at $41.00 per share by selling stockholders affiliated with Blackstone, Carlyle, Hellman & Friedman and ADIA. Underwriters have a 30-day option for an additional 11,250,000 shares.
The offering is expected to close on March 10, 2026. Medline is not selling shares and will not receive proceeds; shares are being sold by the identified selling stockholders.
Positive
- Offering priced at $41.00 per share
- Large placement of 75,000,000 Class A shares
Negative
- Medline will not receive proceeds from the sale
- Underwriters granted a 30-day option for 11,250,000 additional shares
News Market Reaction – MDLN
On the day this news was published, MDLN gained 2.73%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers flagged in the momentum scanner; the -3.4% move with high volume appears stock-specific around this secondary offering.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Secondary launch | Negative | -3.2% | Announcement of 75M-share secondary offering by existing stockholders. |
Prior secondary-offering news on Mar 3, 2026 coincided with a -3.18% move, consistent with the current negative reaction to supply-related headlines.
This announcement prices a large secondary sale by existing Medline holders after the launch of the same offering on Mar 3, 2026, which saw the stock fall 3.18%. That deal followed Medline’s 2025 IPO and strong but mixed earnings, where revenue and EBITDA grew but net income declined. Together, the IPO, earnings updates and now a sizable secondary have kept focus on ownership transitions and liquidity rather than new operating catalysts.
Historical Comparison
The prior secondary-offering launch on Mar 3, 2026 saw a -3.18% move. Today’s pricing-related decline of -3.4% is closely in line with that pattern.
This release prices the same secondary offering of 75,000,000 shares that was launched on Mar 3, 2026, moving the transaction from announcement toward expected closing on Mar 10, 2026.
Market Pulse Summary
This announcement prices a large secondary sale of 75,000,000 Medline Class A shares at $41.00, with an additional 11,250,000-share option for underwriters, all from existing sponsors. Medline receives no proceeds, so the key dynamics are increased tradable float and changing ownership among major holders. Investors may track how this follows the prior day’s launch announcement and fits alongside recent IPO and earnings disclosures.
Key Terms
secondary offering financial
class A common stock financial
underwriters financial
prospectus regulatory
registration statement regulatory
securities and exchange commission regulatory
AI-generated analysis. Not financial advice.
NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of
Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler Financial Group, Inc., R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the offering.
The offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar words or phrases that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainty, and changes in circumstances, many of which are beyond our control, that could cause actual results to differ materially.
Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.
Contacts:
Investor Relations:
Karen King
Global Head Investor Relations
Patrick Flaherty
Director, Investor Relations
(847) 247-7222
IR@medline.com
Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
media@medline.com
Source: Medline Inc.
FAQ
What did Medline (MDLN) announce about the March 2026 secondary offering?
Who is selling the shares in the MDLN March 2026 offering?
Will Medline (MDLN) receive any proceeds from the 75,000,000 share sale?
What is the underwriter option in the MDLN secondary offering and its size?
When is the MDLN secondary offering expected to close and what conditions apply?
